New Zealand Clinical Research
Christchurch, 8011, New Zealand
NCT Number: NCT05970718
The study is researching an experimental drug called REGN7544.The study is focused on healthy adults. The aim of the study is to see how safe and tolerable the study drug is in healthy adults.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Christchurch, 8011, New Zealand
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion / exclusion criteria apply
Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Solution for single ascending IV or SC administration per the protocol
Time frame: Through approximately day 162
Time frame: Through approximately day 162
Time frame: Through day 6
Time frame: Through day 6
Time frame: Through day 6
Time frame: Through day 6
Time frame: Through approximately day 162
Time frame: Through approximately day 162
Time frame: Through approximately day 162
Regeneron Pharmaceuticals
Industry
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7544, an Antagonistic Monoclonal Antibody to NPR1, in Healthy Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details